Laplace Interventional
Medical device company based in Plymouth, MN developing an investigational percutaneous transcatheter tricuspid valve replacement (TTVR) system intended to treat tricuspid regurgitation. The company has progressed through preclinical work to first-in-human procedures and a US Early Feasibility Study, and has advanced both trans-jugular and trans-femoral delivery approaches.
Industries
Nr. of Employees
small (1-50)
Patents
Transcatheter heart valve prosthesis assembled inside heart chambers or blood vessels
US-12279951-B2
View Details
Transcatheter heart valve prosthesis assembled inside heart chambers or blood vessels
US-12279951-B2
View DetailsProducts
Investigational transcatheter tricuspid valve replacement system
A percutaneous prosthetic valve system and associated catheter delivery systems designed for transcatheter implantation in the tricuspid position; supports trans‑jugular and trans‑femoral access, repositionable and retrievable deployment, and designs intended to accommodate varied patient anatomies.
Investigational transcatheter tricuspid valve replacement system
A percutaneous prosthetic valve system and associated catheter delivery systems designed for transcatheter implantation in the tricuspid position; supports trans‑jugular and trans‑femoral access, repositionable and retrievable deployment, and designs intended to accommodate varied patient anatomies.
Services
Support and execution of investigational device implantations within first‑in‑human procedures and an Early Feasibility Study in clinical sites.
Support and execution of investigational device implantations within first‑in‑human procedures and an Early Feasibility Study in clinical sites.
Expertise Areas
- Transcatheter heart valve engineering
- Catheter delivery system development
- Interventional cardiology procedure support
- Clinical trial execution (FIH, Early Feasibility Study)
Key Technologies
- Transcatheter tricuspid valve replacement (TTVR)
- Percutaneous catheter-delivery systems
- Trans‑jugular access (26F)
- Trans‑femoral access
News & Updates
Announcement of completed patient enrollment in the US Early Feasibility Study for the trans‑jugular system and successful treatment of first two patients with the trans‑femoral delivery system.
Series C financing round raising $22M to support transcatheter tricuspid valve technology development.
Public notice that the company began the US Early Feasibility Study of the investigational TTVR system.
Announcement of a successful first‑in‑human procedure in the Early Feasibility Study of the transcatheter tricuspid valve replacement device.
Series B financing of $12.9M to pursue first‑in‑human and clinical feasibility evaluation of the transcatheter valve system.
Series A financing of $7.9M to support preclinical milestones for the transcatheter tricuspid valve technology.
Announcement of completed patient enrollment in the US Early Feasibility Study for the trans‑jugular system and successful treatment of first two patients with the trans‑femoral delivery system.
Series C financing round raising $22M to support transcatheter tricuspid valve technology development.
Public notice that the company began the US Early Feasibility Study of the investigational TTVR system.
Announcement of a successful first‑in‑human procedure in the Early Feasibility Study of the transcatheter tricuspid valve replacement device.
Series B financing of $12.9M to pursue first‑in‑human and clinical feasibility evaluation of the transcatheter valve system.
Series A financing of $7.9M to support preclinical milestones for the transcatheter tricuspid valve technology.